{"id":"vancomycin-capsules","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Anemia"},{"rate":"<5%","effect":"Thrombocytopenia"},{"rate":"<5%","effect":"Renal impairment"},{"rate":"<5%","effect":"Hypokalemia"},{"rate":"<5%","effect":"Hypomagnesemia"},{"rate":"<5%","effect":"Tinnitus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This prevents the incorporation of these precursors into the bacterial cell wall, ultimately leading to cell lysis and death. Vancomycin is a glycopeptide antibiotic that is effective against a wide range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).","oneSentence":"Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:06.424Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of infections caused by susceptible Gram-positive bacteria, including MRSA"}]},"trialDetails":[{"nctId":"NCT04781387","phase":"PHASE2","title":"Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection","status":"COMPLETED","sponsor":"Crestone, Inc","startDate":"2021-01-05","conditions":"Clostridioides Difficile Infection","enrollment":43},{"nctId":"NCT07490054","phase":"PHASE1","title":"Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure","status":"RECRUITING","sponsor":"Melana Yuzefpolskaya, MD","startDate":"2025-09-01","conditions":"Chronic Heart Failure","enrollment":40},{"nctId":"NCT01731236","phase":"EARLY_PHASE1","title":"CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2011-02-11","conditions":"Dietary Modification","enrollment":100},{"nctId":"NCT06889701","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants","status":"RECRUITING","sponsor":"TenNor Therapeutics Inc.","startDate":"2025-04-03","conditions":"Periprosthetic Joint Infection (PJI)","enrollment":33},{"nctId":"NCT06306014","phase":"PHASE1, PHASE2","title":"Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-05-07","conditions":"Clostridioides Difficile Infection, Recurrent Infection","enrollment":56},{"nctId":"NCT06582264","phase":"PHASE1","title":"A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis","status":"COMPLETED","sponsor":"Microbiotica Ltd","startDate":"2024-09-27","conditions":"Ulcerative Colitis","enrollment":29},{"nctId":"NCT07017946","phase":"PHASE1, PHASE2","title":"Intestinal Microbiome Transplant in ALS","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-27","conditions":"Amyotrophic Lateral Sclerosis ALS","enrollment":20},{"nctId":"NCT07341282","phase":"PHASE2","title":"Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2026-01","conditions":"Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC)","enrollment":14},{"nctId":"NCT07328971","phase":"PHASE3","title":"Vancomycin Taper to Prevent Recurrent Clostridioides Difficile","status":"NOT_YET_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-06-01","conditions":"Clostridia Difficile Colitis","enrollment":500},{"nctId":"NCT04729322","phase":"PHASE2","title":"Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-22","conditions":"Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8","enrollment":15},{"nctId":"NCT05370885","phase":"PHASE2","title":"VE202 in Patients With Mild-to-Moderate Ulcerative Colitis","status":"TERMINATED","sponsor":"Vedanta Biosciences, Inc.","startDate":"2023-05-08","conditions":"Ulcerative Colitis, Colitis, Ulcerative","enrollment":114},{"nctId":"NCT06148025","phase":"PHASE4","title":"Antibiotics and Vaccine Immune Responses Study","status":"RECRUITING","sponsor":"South Australian Health and Medical Research Institute","startDate":"2023-11-23","conditions":"Vaccine Response Impaired","enrollment":348},{"nctId":"NCT06817031","phase":"PHASE2","title":"Maternal Probiotic Intervention to Improve Gut Health - Trial II - Bangladesh","status":"ENROLLING_BY_INVITATION","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-04-20","conditions":"Environmental Enteric Dysfunction","enrollment":144},{"nctId":"NCT06126731","phase":"PHASE1, PHASE2","title":"Combination Study of Antibiotics With Enzalutamide (PROMIZE)","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2023-11-02","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":39},{"nctId":"NCT07134790","phase":"PHASE2","title":"Maternal Probiotic Intervention to Improve Gut Health - Trial II - Burkina Faso (MPIGH-II)","status":"RECRUITING","sponsor":"University Ghent","startDate":"2025-07-30","conditions":"Environmental Enteric Dysfunction (EED)","enrollment":144},{"nctId":"NCT04208958","phase":"PHASE1, PHASE2","title":"Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer","status":"COMPLETED","sponsor":"Vedanta Biosciences, Inc.","startDate":"2020-01-23","conditions":"Metastatic Cancer, Melanoma, Gastric Cancer","enrollment":56},{"nctId":"NCT07207434","phase":"PHASE2","title":"Maternal Probiotic Intervention to Improve Gut Health-Trial II-Pakistan","status":"RECRUITING","sponsor":"Aga Khan University","startDate":"2025-08-30","conditions":"Environmental Enteric Dysfunction (EED), Stunting","enrollment":144},{"nctId":"NCT06540391","phase":"PHASE1","title":"A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Microbiotica Ltd","startDate":"2024-08-28","conditions":"Melanoma","enrollment":41},{"nctId":"NCT06979609","phase":"PHASE2, PHASE3","title":"Secondary Prevention of Clostridioides Difficile Using Vancomycin","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2025-10-01","conditions":"Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Clostridoides Difficile Associated Disease","enrollment":300},{"nctId":"NCT05266807","phase":"PHASE3","title":"Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence","status":"RECRUITING","sponsor":"Benoit Guery","startDate":"2023-03-15","conditions":"Clostridioides Difficile Infection","enrollment":220},{"nctId":"NCT06747611","phase":"PHASE2","title":"Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-08-21","conditions":"Alopecia Areata, Alopecia Totalis, Alopecia Universalis","enrollment":40},{"nctId":"NCT05695261","phase":"PHASE2","title":"Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients","status":"RECRUITING","sponsor":"Rima Rachid","startDate":"2023-06-08","conditions":"Allergy, Peanut, Peanut Allergy, Peanut Hypersensitivity","enrollment":37},{"nctId":"NCT07120490","phase":"NA","title":"STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2025-10","conditions":"Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Fecal Microbiota Transplantation (FMT)","enrollment":424},{"nctId":"NCT05690048","phase":"PHASE2","title":"Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)","status":"RECRUITING","sponsor":"Michael Dill","startDate":"2025-07-16","conditions":"Immunotherapy, HCC - Hepatocellular Carcinoma","enrollment":48},{"nctId":"NCT03105479","phase":"PHASE2, PHASE3","title":"Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)","status":"TERMINATED","sponsor":"Actelion","startDate":"2017-04-14","conditions":"Clostridium Difficile Infection","enrollment":1},{"nctId":"NCT05835206","phase":"PHASE2","title":"Further MT for Antibiotic-Resistant Bacterial Colonization in Inpatients","status":"RECRUITING","sponsor":"Emory University","startDate":"2024-04-25","conditions":"Multi-drug Resistant Organism","enrollment":40},{"nctId":"NCT06992453","phase":"NA","title":"Multi-omics Dissection of Gut Microbiome Engraftment During FMT","status":"NOT_YET_RECRUITING","sponsor":"Catholic University of the Sacred Heart","startDate":"2025-06-01","conditions":"Recurrent C. Difficile (rCDI), Ulcerative Colitis (UC), Metabolic Syndrome (MetS)","enrollment":90},{"nctId":"NCT03462459","phase":"PHASE2","title":"Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2018-05-21","conditions":"Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection, CDI","enrollment":79},{"nctId":"NCT06197308","phase":"EARLY_PHASE1","title":"Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2024-03-01","conditions":"Primary Sclerosing Cholangitis","enrollment":28},{"nctId":"NCT06030219","phase":"PHASE1","title":"Microbiome Effect of Omadacycline on Healthy Volunteers","status":"COMPLETED","sponsor":"University of Houston","startDate":"2020-10-12","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT04246151","phase":"EARLY_PHASE1","title":"Oral Vancomycin Versus Probiotics Versus Placebo for Prevention of Clostridium Difficile Infection in Colonized Patients","status":"WITHDRAWN","sponsor":"Hamilton Health Sciences Corporation","startDate":"2022-09-01","conditions":"Clostridium Difficile Colonization, Clostridium Difficile Diarrhea","enrollment":""},{"nctId":"NCT04899115","phase":"PHASE2","title":"VE303 for Treatment of Hepatic Encephalopathy (HE)","status":"COMPLETED","sponsor":"Patricia Bloom","startDate":"2021-08-06","conditions":"Cirrhosis, Hepatic Encephalopathy","enrollment":19},{"nctId":"NCT01987895","phase":"PHASE3","title":"Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea","status":"COMPLETED","sponsor":"Actelion","startDate":"2014-03-27","conditions":"Clostridium Difficile Infection","enrollment":632},{"nctId":"NCT01983683","phase":"PHASE3","title":"Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea","status":"COMPLETED","sponsor":"Actelion","startDate":"2013-12-12","conditions":"Clostridium Difficile Infection","enrollment":631},{"nctId":"NCT03617445","phase":"PHASE2","title":"Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2022-08-03","conditions":"Clostridium Difficile Infection Recurrence","enrollment":3},{"nctId":"NCT05320068","phase":"PHASE3","title":"Oral Vancomycin Vs Placebo in the Prevention of Recurrence of Clostridioides Difficile's Infection","status":"COMPLETED","sponsor":"Julia Orígüen","startDate":"2022-08-02","conditions":"Clostridioides Difficile Infection","enrollment":24},{"nctId":"NCT02218372","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2015-01-09","conditions":"Clostridium Difficile-associated Diarrhea (CDAD)","enrollment":148},{"nctId":"NCT06702345","phase":"NA","title":"Clostridioides Difficile Controlled Human Infection Model","status":"NOT_YET_RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-03-01","conditions":"C. Difficile, C. Difficile Infection, Controlled Human Infection","enrollment":60},{"nctId":"NCT02254967","phase":"PHASE4","title":"A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2014-11-06","conditions":"Clostridium Difficile","enrollment":364},{"nctId":"NCT05770726","phase":"NA","title":"Probiotics Administration Via Colonoscopic Spray and Oral Administration in CDAD Patients","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2023-04-21","conditions":"Diarrhea Infectious","enrollment":60},{"nctId":"NCT05354102","phase":"PHASE1","title":"A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biomica Ltd.","startDate":"2022-05-01","conditions":"Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma","enrollment":11},{"nctId":"NCT06398379","phase":"NA","title":"Virus as Treatment of C. Difficile Infection (VISION)","status":"NOT_YET_RECRUITING","sponsor":"Copenhagen University Hospital, Hvidovre","startDate":"2024-05-01","conditions":"Clostridium Difficile Infections","enrollment":40},{"nctId":"NCT05709184","phase":"NA","title":"Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infection","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2023-11-15","conditions":"Clostridioides Difficile Infection","enrollment":196},{"nctId":"NCT04968951","phase":"EARLY_PHASE1","title":"Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)","status":"TERMINATED","sponsor":"Ari M Grinspan","startDate":"2021-11-10","conditions":"Ulcerative Colitis, FMT, Fecal Microbiota Transplant","enrollment":4},{"nctId":"NCT05576961","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of RX-af01 Combined With PD-1 Antibody","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-09-15","conditions":"Solid Tumor, Immune Checkpoint Inhibitor, Intestinal Flora","enrollment":60},{"nctId":"NCT06213480","phase":"NA","title":"Next-Generation Synbiotic in Individuals With Overweight or Obesity","status":"UNKNOWN","sponsor":"Texas Christian University","startDate":"2024-01-10","conditions":"Overweight and Obesity","enrollment":60},{"nctId":"NCT00756262","phase":"PHASE1","title":"Probiotic Lactobacillus GG to Eliminate VRE Colonization","status":"TERMINATED","sponsor":"Tufts Medical Center","startDate":"2003-03","conditions":"Vancomycin Resistant Enterococcal Colonization","enrollment":11},{"nctId":"NCT05693077","phase":"PHASE1","title":"Clostridioides Difficile Colonisation","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2023-09-22","conditions":"Clostridioides Difficile Infection","enrollment":70},{"nctId":"NCT05447533","phase":"NA","title":"Clostridioides Difficile and Frailty","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2022-09-16","conditions":"Frail Elderly, Clostridioides Difficile, Geriatric Assessment","enrollment":217},{"nctId":"NCT01598311","phase":"PHASE3","title":"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2012-05-16","conditions":"Clostridium Difficile Infection","enrollment":608},{"nctId":"NCT03673956","phase":"PHASE1, PHASE2","title":"Topical Antibiotics in Chronic Rhinosinusitis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-09-26","conditions":"Chronic Rhinosinusitis (Diagnosis)","enrollment":19},{"nctId":"NCT03795233","phase":"PHASE1, PHASE2","title":"Fecal Microbiota Transplant for Primary CDI","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-08-23","conditions":"Clostridium Difficile Infection","enrollment":5},{"nctId":"NCT03827447","phase":"PHASE1","title":"Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2019-07-17","conditions":"Clostridium Difficile Infection","enrollment":7},{"nctId":"NCT03006809","phase":"PHASE1","title":"Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis","status":"COMPLETED","sponsor":"Najwa Elnachef","startDate":"2017-03-02","conditions":"Ulcerative Colitis","enrollment":30},{"nctId":"NCT03452189","phase":"PHASE2","title":"The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2017-11-27","conditions":"End Stage Renal Disease","enrollment":15},{"nctId":"NCT03939273","phase":"NA","title":"The Effects of Gut Micribiota Disruption on the Immune Response After Open Heart Surgery","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2022-03","conditions":"Systemic Inflammatory Response Syndrome, Postoperative Shock, Coronary Artery Disease","enrollment":80},{"nctId":"NCT03643887","phase":"PHASE2","title":"Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2022-09-01","conditions":"Clostridium Difficile Infection","enrollment":""},{"nctId":"NCT03030248","phase":"PHASE2","title":"Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2018-06-01","conditions":"Clostridium Difficile Infection, Hematologic Diseases, Bone Marrow Transplant","enrollment":9},{"nctId":"NCT02241421","phase":"NA","title":"The Importance of the Gut Microbiota in Body Weight Control and Insulin Sensitivity","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2012-04","conditions":"Obesity, Insulin Resistance","enrollment":57},{"nctId":"NCT02865616","phase":"PHASE1","title":"MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)","status":"COMPLETED","sponsor":"NuBiyota","startDate":"2017-10-27","conditions":"Clostridium Difficile Infection","enrollment":19},{"nctId":"NCT03063437","phase":"PHASE2","title":"A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization","status":"COMPLETED","sponsor":"Microbiome Health Research Institute","startDate":"2017-08-17","conditions":"Antibiotic Resistant Strain","enrollment":9},{"nctId":"NCT03822819","phase":"NA","title":"Investigation of the Optimal Cocktailed Probiotics for Decolonization of Vancomycin-resistant Enterococci in Human Gut","status":"UNKNOWN","sponsor":"Taipei Medical University Shuang Ho Hospital","startDate":"2019-03-15","conditions":"Vancomycin-Resistant Enterococci, Probiotics","enrollment":100},{"nctId":"NCT04236778","phase":"PHASE1","title":"First-in-human Study of VE303 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Vedanta Biosciences, Inc.","startDate":"2017-11-28","conditions":"Healthy Volunteers","enrollment":39},{"nctId":"NCT01775397","phase":"PHASE4","title":"A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System","status":"TERMINATED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2012-11-29","conditions":"Clostridium Difficile","enrollment":12},{"nctId":"NCT02426918","phase":"PHASE2","title":"Study of Debio 1450 for Bacterial Skin Infections","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2015-05","conditions":"Bacterial Infections","enrollment":330},{"nctId":"NCT02384200","phase":"PHASE4","title":"A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2015-03","conditions":"Nephrolithiasis, Urinary Tract Infections","enrollment":86},{"nctId":"NCT01597505","phase":"PHASE3","title":"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2012-05-16","conditions":"Clostridium Difficile Infection","enrollment":606},{"nctId":"NCT03046901","phase":"NA","title":"Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients","status":"WITHDRAWN","sponsor":"Ochsner Health System","startDate":"2016-12-07","conditions":"Primary Sclerosing Cholangitis, Post- Orthotopic Liver Transplantation","enrollment":""},{"nctId":"NCT03403972","phase":"PHASE1","title":"Evaluate the Effects of the Environmental Change in Intestine by Antibiotics on the Pharmacokinetic Characteristics of Simvastatin in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2017-12-06","conditions":"Simvastatin Pharmacokinetics and Gut Microbiome","enrollment":6},{"nctId":"NCT02774382","phase":"PHASE3","title":"Rectal Bacteriotherapy, Fecal Microbiota Transplantation or Oral Vancomycin Treatment of Recurrent Clostridium Difficile Infections","status":"UNKNOWN","sponsor":"Hvidovre University Hospital","startDate":"2017-05-01","conditions":"Clostridium Difficile","enrollment":450},{"nctId":"NCT01222702","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Actelion","startDate":"2011-01-25","conditions":"Clostridium Difficile Infection","enrollment":84},{"nctId":"NCT00468728","phase":"PHASE3","title":"PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2006-10-04","conditions":"Clostridium Infections, Diarrhea","enrollment":535},{"nctId":"NCT00314951","phase":"PHASE3","title":"Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)","status":"COMPLETED","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2006-05-02","conditions":"Clostridium Infections, Diarrhea","enrollment":629},{"nctId":"NCT02092935","phase":"PHASE2","title":"A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)","status":"COMPLETED","sponsor":"Summit Therapeutics","startDate":"2014-04","conditions":"Clostridium Difficile Infection","enrollment":100},{"nctId":"NCT02355938","phase":"PHASE4","title":"Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2014-02","conditions":"Clostridium Difficile, Spinal Cord Injury","enrollment":12},{"nctId":"NCT00384527","phase":"PHASE3","title":"Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease","status":"TERMINATED","sponsor":"Romark Laboratories L.C.","startDate":"2006-12","conditions":"Clostridium Infections","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"DRUG INEFFECTIVE"},{"count":2,"reaction":"ABDOMINAL PAIN"},{"count":2,"reaction":"PRODUCT PHYSICAL ISSUE"},{"count":1,"reaction":"ANAL INCONTINENCE"},{"count":1,"reaction":"ASCITES"},{"count":1,"reaction":"CLOSTRIDIUM DIFFICILE INFECTION"},{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"DEATH"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"DRUG EFFECT DECREASED"}],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vancomycin capsules","genericName":"Vancomycin capsules","companyName":"Astellas Pharma Europe B.V.","companyId":"astellas-pharma-europe-b-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors. Used for Treatment of infections caused by susceptible Gram-positive bacteria, including MRSA.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}